Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

AC Immune (ACIU) Return on Capital Employed: 2016-2025

Historic Return on Capital Employed for AC Immune (ACIU) over the last 9 years, with Sep 2025 value amounting to 5.58%.

  • AC Immune's Return on Capital Employed rose 585.00% to 5.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.58%, marking a year-over-year increase of 585.00%. This contributed to the annual value of -0.50% for FY2024, which is 17.00% down from last year.
  • Per AC Immune's latest filing, its Return on Capital Employed stood at 5.58% for Q3 2025, which was up 1,232.64% from -0.49% recorded in Q2 2025.
  • In the past 5 years, AC Immune's Return on Capital Employed ranged from a high of 5.58% in Q3 2025 and a low of -8.07% during Q1 2025.
  • In the last 3 years, AC Immune's Return on Capital Employed had a median value of -0.42% in 2024 and averaged -0.57%.
  • Within the past 5 years, the most significant YoY rise in AC Immune's Return on Capital Employed was 585bps (2025), while the steepest drop was 773bps (2025).
  • Quarterly analysis of 5 years shows AC Immune's Return on Capital Employed stood at -0.00% in 2021, then crashed by 39bps to -0.39% in 2022, then increased by 4bps to -0.35% in 2023, then fell by 7bps to -0.42% in 2024, then skyrocketed by 585bps to 5.58% in 2025.
  • Its Return on Capital Employed stands at 5.58% for Q3 2025, versus -0.49% for Q2 2025 and -8.07% for Q1 2025.